Abstract

BackgroundLiver biopsy is the gold standard for detecting the degree of liver fibrosis; however, invasiveness constitutes its main limiting factor in clinical application, so we aimed to evaluate the non-invasive biomarker formulas (APRI and FIB-4) and their modified forms by BMI z-score (M-APRI, M-FIB-4, and B-AST) compared to liver biopsy in the assessment of liver fibrosis in children with chronic liver diseases. Two hundred children aged 6.3 ± 3.8 years (98 males, 102 females) with chronic liver diseases underwent liver biopsy. The stage of fibrosis was assessed according to the METAVIR system for all children, and the following non-invasive biomarker formulas were calculated: APRI, modified APRI (M-APRI: BMI z-score × APRI), Fibrosis-4 index (FIB-4), modified FIB-4 (M-FIB-4: BMI z-score × FIB-4), and B-AST (BMI z-score × AST). The best cutoff value was calculated to detect early fibrosis (F1–F2) from advanced liver fibrosis (F3–F4).ResultsThere were positive correlations between all studied non-invasive biomarker models (APRI, FIB-4, M-APRI, M-FIB-4, B-AST) and fibrosis score as an increase in fibrosis score was associated with an increase in mean ± SD of all studied biomarker formulas. The best cutoff values of non-invasive biomarker models in the diagnosis of early fibrosis (F1–F2) were APRI > 0.96, M-APRI > 0.16, FIB-4 > 0.019, M-FIB-4 > 0.005, and B-AST > −8 with an area under the curve above 0.7 each, while the best cutoff values of non-invasive biomarker models (APRI, M-APRI, FIB-4, M-FIB-4, and B-AST) in the diagnosis of advanced liver fibrosis (F3–F4) were >1.96, >2.2, >0.045, and >0.015, >92.1, respectively, with an area under the curve above 0.8 each.ConclusionAPRI, M-APRI, FIB-4, M-FIB-4, and B-AST are good non-invasive alternatives to liver biopsy in the detection of liver fibrosis in children with chronic liver diseases of different etiologies especially those that include BMI z-scores in their formulas.

Highlights

  • Liver biopsy is the gold standard for detecting the degree of liver fibrosis; invasiveness constitutes its main limiting factor in clinical application, so we aimed to evaluate the non-invasive biomarker formulas (APRI and Fibrosis-4 index (FIB-4)) and their modified forms by BMI z-score (M-aminotransferase/platelet ratio index (APRI), modified FIB-4 (M-FIB-4), and B-AST) compared to liver biopsy in the assessment of liver fibrosis in children with chronic liver diseases

  • Behairy et al Egyptian Pediatric Association Gazette (2021) 69:26 screening tools to predict fibrosis. Fibrosis scores such as aspartate aminotransferase/platelet ratio index (APRI) and fibrosis index based on four factors (Fibrosis-4 index, FIB-4) were developed based on the progression of liver pathology to cirrhosis and derived from the Apricot database in patients with chronic hepatitis C virus (HCV) infection [4]

  • In this study, we aimed at the evaluation of non-invasive serum biomarker fibrosis models (APRI and FIB-4) and their modified forms by BMI z-score (M-APRI, M-FIB-4, and B-AST), compared to liver biopsy to assess liver fibrosis in children with chronic liver diseases

Read more

Summary

Introduction

Liver biopsy is the gold standard for detecting the degree of liver fibrosis; invasiveness constitutes its main limiting factor in clinical application, so we aimed to evaluate the non-invasive biomarker formulas (APRI and FIB-4) and their modified forms by BMI z-score (M-APRI, M-FIB-4, and B-AST) compared to liver biopsy in the assessment of liver fibrosis in children with chronic liver diseases. Behairy et al Egyptian Pediatric Association Gazette (2021) 69:26 screening tools to predict fibrosis Fibrosis scores such as aspartate aminotransferase/platelet ratio index (APRI) and fibrosis index based on four factors (Fibrosis-4 index, FIB-4) were developed based on the progression of liver pathology to cirrhosis and derived from the Apricot database in patients with chronic hepatitis C virus (HCV) infection [4]. In this study, we aimed at the evaluation of non-invasive serum biomarker fibrosis models (APRI and FIB-4) and their modified forms by BMI z-score (M-APRI, M-FIB-4, and B-AST), compared to liver biopsy to assess liver fibrosis in children with chronic liver diseases

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call